II - In-house lobbyists and trade/business/professional associations
Companies & groups
Novo Allé, 1
Mr Lars Rebien Sørensen
Mr Morten Frank Pedersen
Novo Nordisk is a global healthcare company with over 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 40000 employees in 75 countries. It markets products and services that make a significant difference to patients, the medical profession and society in 190 countries.
Novo Nordisk is committed to developing its business towards environmental, social and financial sustainability (the triple bottom line). This commitment is demonstrated through its values and its environmental and social responsibility policies.
The Novo Nordisk Foundation is a non-profit institution, whose formal purpose is to provide a stable basis for its company's operations and to make contributions to scientific, humanitarian and social progress.
Novo A/S is an unlisted Danish public limited liability company, owned by the Novo Nordisk Foundation and established to manage the Foundation's funds and to invest actively in other companies.
All A and B shares in Novo Nordisk A/S, previously held by the Novo Nordisk Foundation, were transferred to Novo A/S on 31 December 1999. Novo Nordisk’s B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
EMA Roadmap 2015-2020
EC Study on off-label use of medicines
Medical Devices Regulation
EC Study on environmental risks of medicinal products
General Data Protection Regulation
Shareholder Rights Directive
CCCTB Commission Proposal
Novo Nordisk's goals with its involvement with EU institutions are:
- to improve conditions for prevention, treatment and care in Europe to address unmet needs
- to support the voice of people living with or at risk of
- to increase Europe´s competitiveness as a location for Research and Development
50%: 2 25%: 2
|First name||Surname||Start Date||End Date|
|Ane Sofie Böhm||NIELSEN||23/09/2014||19/09/2015|
Novo Nordisk is member of:
EFPIA - European Federation of Pharmaceutical Industries and Associations
EBE - European Biopharmaceutical Enterprises
EuropaBio - European Association for Bioindustries
Danish Chamber of Commerce
01/2014 - 12/2014
50,000 € - 99,999 €
No funding received from the EU institutions during the last closed financial year.
By its registration the organisation has signed the Transparency Register Code of Conduct.
The organisation has also declared to be bound to the following other Code:
All EFPIA Codes The Novo Nordisk Way (http://www.novonordisk.com/about_us/novo_nordisk_way/nnway_about.asp) Novo Nordisk Business Ethics Policy (http://www.novonordisk.com/about_us/Novo_Nordisk_Way/our-policies.asp)